Taken together, direct targeting of STAT3/5 through dual STAT3/5 degraders and/or broad‐range kinase inhibition, by indirect targeting of STAT3/5 nuclear shuttling, could pave the road for novel therapeutic options for L‐CTCL. Here, STAT3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.